Loading
Every dated change on the records linked to Non-metastatic castration-resistant prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Non-metastatic CRPC
Darolutamide lengthened metastasis-free and overall survival compared with placebo with a near-placebo side-effect profile; approved in July 2019.
A milestone in how this cancer is treated.
Non-metastatic CRPC (SPARTAN)
Non-metastatic CRPC
Median metastasis-free survival 40.
Enzalutamide lengthened metastasis-free survival and, with longer follow-up, overall survival compared with placebo; approved in July 2018.
A milestone in how this cancer is treated.